Introduction:

Oncology Biosimilar Treatment Market was valued at US$ 5.1 billion in 2024 and is projected to grow at a CAGR of 11.2% to reach US$ 14.7 billion by 2034.

Biosimilar are similar to biological medicine which contains active substance from a biological source such as organisms or living cells. They are large, complex structure, possesses potential structural variations and requires large number of clinical trials. It is also referred as bio generics. It is bio therapeutic product which is similar in term of safety, quality and efficacy to the reference bio therapeutic products. Many biologics are also produced using recombinant DNA technology.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Oncology Biosimilar Treatment Market Key Drivers:

Increasing number of collaborative agreement for development and manufacturing for biosimilar are the sources boosting up the target market. Also, growing demand for cost effective treatment for oncology are the major factors serving as the key drivers for the oncology biosimilar treatment market. Moreover, increasing number of cases for cancer such as breast cancer, cervical cancer, lung cancer, stomach cancer globally, in turn is expected to drive the oncology biosimilar treatment market over the forecast period. Increased demand for the healthcare facilities and rapid approval of biosimilar will support the growth of oncology biosimilar market in the near future.

Oncology Biosimilar Treatment Market Restrains

Manufacturing companies have to launch the product after patent expiration of reference biologic which is expected to limit the market growth. In addition, high manufacturing cost and time required for development of oncology biosimilar, along with high cost for development is expected to restrain the market growth over the forecast period. 

The oncology biosimilar treatment market has been segmented on the basis of product, cancer, distribution channel, and region. On the basis of product type, the oncology biosimilar treatment market is consisted of monoclonal antibody, immunomodulators and others. Based on the cancer type, the target market is segmented as blood cancer, breast cancer, lung cancer, cervical cancer, colorectal cancer, kidney cancer, and others. Based on the distribution channel, the target market is comprising of hospital pharmacies, online pharmacies, retail pharmacies.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

On the basis of region, the oncology biosimilar treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America contributes major market share and expected to maintain its dominance over the forecast period. This is attributed to the increasing incidence of cancer, developed healthcare infrastructure, favorable government initiatives, and increasing number of approvals in the region. Robust pipeline by leading market players and launch for the same in US and Canada is expected to drive the market growth in the region. Europe accounts for second-largest revenue share contribution to the oncology biosimilar treatment market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively. Asia Pacific is expected to witness rapid growth rate over the forecast period. This is attributed owing to increasing number of cancer cases and growing for demand for cost effective treatment in the region.

Report Scope:

Attribute	Details
Market Size 2024	US$ 5.1 billion
Projected Market Size 2034	US$ 14.7 billion
CAGR Growth Rate	11.2%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Product - Monoclonal Antibody, Immunomodulators and Others By Cancer - Blood Cancer, Breast Cancer, Lung Cancer, Cervical Cancer, Colorectal cancer, Kidney cancer, and Others By Distribution Channel - Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Oncology Biosimilar Treatment Market report based on product, cancer, distribution channel, and region:

Oncology Biosimilar Treatment Market, By Product:

• Monoclonal Antibody
• Immunomodulators
• Others

Oncology Biosimilar Treatment Market, By Cancer:

• Blood Cancer
• Breast Cancer
• Lung Cancer
• Cervical Cancer
• Colorectal cancer
• Kidney cancer
• Others

Oncology Biosimilar Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Oncology Biosimilar Treatment Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Key players contributing to oncology biosimilar treatment market are Mylan N.V., F Hoffmann-La Roche, Biogen Inc., Biocon Limited., Novartis AG, Celltrion Healthcare, Plc, Amgen Inc., Pfizer Inc., Allergan and Teva Pharmaceutical Industries Ltd.

Recent Development:

• In June 2023, Enzene Biosciences, Pune based subsidiary of Alkem Laboratories launched Bevacizumab, a biosimilar of Avastin used for treatment of metastatic colorectal cancer. It acts as a alternative to expensive Avastin biologic. Bevacizumab is the sixth biosimilar from Enzene Biosciences.
• In March 2023, The FDA and the European Medicines Agency (EMA) accepted applications for a trastuzumab biosimilar and an ustekinumab biosimilar, respectively. HLX02 will become the sixth trastuzumab biosimilar to receive regulatory approval and it will be used to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer. It will also be used in patients with HER2-positive metastatic gastric cancer.

• Biocon Limited *
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Mylan N.V.
• F Hoffmann-La Roche
• Biogen Inc.
• Novartis AG
• Celltrion Healthcare
• Plc
• Amgen Inc.
• Pfizer Inc.
• Allergan
• Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
   • PORTER’s
   • Investment Outlook
3. Market Purview
   • Executive Summary
   • Key Findings—Global Outlook for Global Oncology Biosimilar Treatment Market Strategies
     • Key Questions this Study will Answer

     • By Product (Monoclonal Antibody, Immunomodulators and Others)

       By Cancer (Blood Cancer, Breast Cancer, Lung Cancer, Cervical Cancer, Colorectal cancer, Kidney cancer, and Others)

       By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)

   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Overview
   • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
   • Y-o-Y Growth Analysis (%), 2020 – 2030
   • Regional Trends
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Regional Analysis
   • Regional Revenue Analysis
   • Regional By segment Analysis
   • Reasons for regional growth
   • Key Player of particular region
   • Countries Include in the report:

1. • • North America (U.S., Canada)
     • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
     • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
     • Latin America (Brazil, Mexico, Rest of Latin America)
     • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
   • Competitive Overview
   • Competitive Benchmarking
   • Market Share Analysis
   • Key Developments In The Global Global Oncology Biosimilar Treatment Market Market
   • Key Developments: Mergers & Acquisitions
   • Key Developments: Collaboration
   • Key Developments: Contracts & Agreements
   • Key Developments: Expansion
   • Key Developments: Product Developments
2. Company Profiles

 

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies
• SWOT Analysis

• Mylan N.V., F Hoffmann-La Roche, Biogen Inc., Biocon Limited., Novartis AG, Celltrion Healthcare, Plc, Amgen Inc., Pfizer Inc., Allergan and Teva Pharmaceutical Industries Ltd.

1. The Last Word
   • Future Impact
   • About Us
   • Contact